Activated dendritic cells: key players in the immune response against cancer

by | Nov 18, 2026 | Publications | 0 comments

Our immune system has the remarkable ability to recognise and eliminate cancer cells, yet tumours often develop ways to escape immune control. Understanding why some immune responses succeed while others fail is essential for developing more effective cancer treatments.

Dendritic cells are specialised immune cells that play a central role in this process. They capture and present antigens to T cells, providing the signals needed to initiate and sustain immune responses against cancer. However, the importance of the activation state of dendritic cells in determining their ability to stimulate effective anti-tumour immunity has remained unclear.

In a study published in Immunity, driven by Dr Maria Koufaki in Professor Santiago Zelenay‘s group at the Cancer Research UK Manchester Institute, the team investigated the role in anti-tumour immunity of a population of dendritic cells previously identified in tumours and other tissues, and variously referred to as mregDCs, mDCs or CCR7+ DCs. These cells share a distinctive activation programme, leading the team to refer to them as activated dendritic cells (actDCs), but their precise contribution to anti-tumour immunity has remained unclear. To investigate their function, the team developed innovative genetically engineered mouse models that allowed them to selectively identify, track and eliminate these cells.

The findings revealed that the ability of dendritic cells to effectively stimulate CD8+ T cells, which can recognise and kill cancer cells, is largely restricted to this activated state. Importantly, both major dendritic cell lineages can acquire this state, although they use distinct antigen presentation mechanisms to stimulate CD8+ T cells.

The researchers also discovered that actDCs are essential not only for initiating CD8+ T cell responses in tumour-draining lymph nodes but also for maintaining the function of these cells within tumours. Removing actDCs severely compromised the immune system’s ability to control cancer and reduced the effectiveness of immunotherapies, including immune checkpoint inhibitors and adoptive T cell therapy.

One of the most important findings of our study is that the ability of dendritic cells to stimulate anti-tumour immunity depends not just on what type of cell they are, but also on their activation state. Understanding what drives this activation and how we might manipulate it could open new opportunities to improve cancer immunotherapy. The study establishes actDCs as essential orchestrators of anti-tumour immunity and provides new experimental tools to investigate their biology and therapeutic potential.

Professor Santiago Zelenay, senior author and lead of the Cancer Immunology Branch at the Lydia Becker Institute of Immunology and Inflammation

This research was published in Immunity (August 2026). Full title of the paper: CCR7+ activated dendritic cells are essential for spontaneous and immunotherapy-driven anti-tumor immunity.

Illustration by Anna Pidoux, a PhD student in the Zelenay Lab Group.

0 Comments